Axon

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Retrieved on: 
Tuesday, March 5, 2024

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein (GFAP) compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB (reduction in GFAP associated with improvement in CDR-SB, and increase in GFAP associated with worsening in CDR-SB). These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024. In addition, academic researchers from UCL will be presenting data in a separate poster at the meeting demonstrating that p38MAPK inhibition, including with neflamapimod specifically, improves tau-induced axonal transport defects both in vitro and in a tauopathy mouse model.

Key Points: 
  • These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024.
  • “The effects on GFAP, particularly the association between GFAP response and clinical outcomes, further support that neflamapimod is clinically efficacious in patients with DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
  • A PDF copy of the GFAP poster presentation will be available on the “ Presentations and Publications ” section of the CervoMed website.
  • Title: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

Alli Connect Welcomes Esteemed Public Safety Leaders as New Advisors to Accelerate Impact of Tactical Wellness Technology

Retrieved on: 
Wednesday, February 28, 2024

Clay Winn , the General Manager of Strategic Relations at Axon , the global leader in public safety technology, brings to Alli Connect over 20 years of industry experience.

Key Points: 
  • Clay Winn , the General Manager of Strategic Relations at Axon , the global leader in public safety technology, brings to Alli Connect over 20 years of industry experience.
  • Winn is a public safety pioneer of solutions that protect and empower first responders.
  • Winn emphasized the unique vision behind Alli Connect, "I was immediately drawn to Alli Connect's mission upon meeting Colleen Hilton.
  • His work in shaping policy, enhancing labor relations, and promoting wellness initiatives has had a profound impact on the public safety community and make him an invaluable asset to Alli Connect.

Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference

Retrieved on: 
Thursday, February 15, 2024

AMX0035 is marketed by Amylyx as RELYVRIO® and is approved to treat ALS in adults in the U.S. and approved with conditions as ALBRIOZA™ for the treatment of ALS in Canada.

Key Points: 
  • AMX0035 is marketed by Amylyx as RELYVRIO® and is approved to treat ALS in adults in the U.S. and approved with conditions as ALBRIOZA™ for the treatment of ALS in Canada.
  • This poster shares details on pre-clinical efficacy studies as well as introduces the design approach for the first-in-human study, anticipated to begin later this year.
  • The Company is studying multiple cellular pathways implicated in disease pathogenesis as we believe that it is going to take a combination approach to find a cure for ALS.
  • Additional information, including copies of the poster presentations, will be made available on the “ Publications ” tab of the Amylyx website, following the conclusion of the poster presentations.

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

Retrieved on: 
Tuesday, February 6, 2024

Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announces its management will be participating in Baird’s Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 10:30AM EST.

Key Points: 
  • Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announces its management will be participating in Baird’s Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 10:30AM EST.
  • The speakers will cover two key topics – first, they will provide an update on the unique features of the Company’s  ongoing blinded, randomized, placebo-controlled Phase II trial for Early Alzheimer's disease (MCI/Mild AD).
  • Baird’s Biotech Discovery Series, which launched in early 2022, is an opportunity for investors to hear directly from interesting and innovative public and private biotech companies in a fireside chat format.
  • We invite key members of management and frequently ask related third parties to join the discussion to learn why they are excited about the science and opportunity for these emerging biotech leaders.

Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset

Retrieved on: 
Monday, January 15, 2024

Neuraptive Therapeutics Inc., a leader in innovative medical solutions, is pleased to announce that it has received Orphan Drug Designation from the United States (US) Food and Drug Administration (FDA) for its fusogen contained in the NTX-001 treatment kit.

Key Points: 
  • Neuraptive Therapeutics Inc., a leader in innovative medical solutions, is pleased to announce that it has received Orphan Drug Designation from the United States (US) Food and Drug Administration (FDA) for its fusogen contained in the NTX-001 treatment kit.
  • Dr. Seth Schulman, Chief Medical Officer of Neuraptive Therapeutics Inc., stated, “Receiving the Orphan Drug Designation for NTX-001 is a testament to our commitment to advancing healthcare solutions for patients impacted by peripheral nerve injuries who today have limited options.” The Orphan Drug Designation is granted to drugs intended to treat rare diseases or conditions in the US.
  • Highlights of Orphan Designation are:
    Eligibility to receive regulatory assistance and guidance from the FDA in the design of an overall drug development plan.
  • “ Following this designation, Neuraptive Therapeutics plans to accelerate the development of NTX-001, aiming to bring this promising treatment to patients as soon as possible.” Said Mr. Tzanis.

Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves

Retrieved on: 
Monday, January 8, 2024

Neuraptive Therapeutics, Inc. is dedicated to revolutionizing patient care through innovative therapies, and NTX-001 has the potential to redefine the standard of care.

Key Points: 
  • Neuraptive Therapeutics, Inc. is dedicated to revolutionizing patient care through innovative therapies, and NTX-001 has the potential to redefine the standard of care.
  • Key highlights from the NEUROFUSE Study:
    The NEUROFUSE Study is a 48-week, Multicenter, Randomized, Controlled, Evaluator-Blinded Study comparing NTX-001 as an adjunct treatment to standard of care vs. standard of care alone.
  • The study was to enroll 60 patients, and patients were randomized in a 1:1 ratio between treatments.
  • For more information about Neuraptive Therapeutics, Inc., and our pioneering work in peripheral nerve injury treatments, please visit Neuraptive.com.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Axon Enterprise, Inc. (NASDAQ: AXON) and Encourages Long-Term Investors to Contact the Firm

Retrieved on: 
Monday, January 8, 2024

Shareholder protection law firm Kaskela Law LLC announces that it is investigating Axon Enterprise, Inc. (NASDAQ: AXON) (“Axon”) on behalf of the company’s long-term investors.

Key Points: 
  • Shareholder protection law firm Kaskela Law LLC announces that it is investigating Axon Enterprise, Inc. (NASDAQ: AXON) (“Axon”) on behalf of the company’s long-term investors.
  • Long-term Axon stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation.
  • For additional information about Kaskela Law LLC please visit www.kaskelalaw.com .

Verizon accelerates network slicing technology with new public safety use case

Retrieved on: 
Tuesday, November 28, 2023

Network slicing is a technology that allows customers to send data over virtual end-to-end networks tailored to specific application requirements, while also optimizing network performance to support all services.

Key Points: 
  • Network slicing is a technology that allows customers to send data over virtual end-to-end networks tailored to specific application requirements, while also optimizing network performance to support all services.
  • The other test was run simultaneously over Verizon’s commercial 5G Ultra Wideband network without network slicing.
  • Compared to Verizon’s commercial 5G Ultra Wideband network, services on the network slice showed:
    “This most recent network slicing demonstration shows one of many use cases where network slicing can be a game-changer for our enterprise, public sector, and Verizon Frontline customers,” said Adam Koeppe, SVP of Network and Technology Planning for Verizon.
  • In each case, using network slicing, Verizon would be able to better match network performance to application requirements.

Cognito Therapeutics Phase 2 OVERTURE Study MRI Imaging Analysis Published in Journal of Alzheimer’s Disease

Retrieved on: 
Monday, December 11, 2023

Cognito Therapeutics , a neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced today publication of MRI imaging data from its Phase 2 OVERTURE study in the Journal of Alzheimer’s Disease .

Key Points: 
  • Cognito Therapeutics , a neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced today publication of MRI imaging data from its Phase 2 OVERTURE study in the Journal of Alzheimer’s Disease .
  • White matter volume assessments were performed using T1-weighted MRI, and myelin content assessments were performed using T1-weighted/T2-weighted MRI ratios.
  • “Our Phase 2 OVERTURE study imaging results published in the Journal of Alzheimer's Disease, show that our proprietary gamma sensory stimulation reduced white matter atrophy and preserved brain myelin content in patients.
  • The Company’s lead therapy is currently in a pivotal study (HOPE) in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation.

Deepcell Garners Industry Recognition for Disruptive AI-Driven Approach to Single Cell Morphology Analysis

Retrieved on: 
Tuesday, November 14, 2023

Deepcell , a pioneer in artificial intelligence (AI)-powered single-cell analysis to fuel deep biological discoveries, today shared the news of two significant industry recognitions as it prepares for upcoming scientific meetings.

Key Points: 
  • Deepcell , a pioneer in artificial intelligence (AI)-powered single-cell analysis to fuel deep biological discoveries, today shared the news of two significant industry recognitions as it prepares for upcoming scientific meetings.
  • Earlier this year, Deepcell launched the REM-I platform , a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, Human Foundation Model, and Axon data suite.
  • By bringing together single cell imaging, sorting, and high-dimensional analysis, the REM-I platform catalyzes new methods of discovery in a wide range of fields including cancer biology, developmental biology, stem cell biology, gene therapy and functional screening, among others.
  • Deepcell’s REM-I platform was selected as "Cell Imaging Product of the Year," one of only four breakthrough innovations in the field of cell biology, in the third annual BioTech Breakthrough Awards.